James Hughes, dean of the Bloustein School of Planning & Public Policy at Rutgers University, also said he did not see much duplication to be cut.
“Allergan has a sales staff that deals with their specific products, and Pfizer has its staff for different products. So I would think that staff is going to stay intact,” Hughes said. “It shouldn’t have much of an impact one way or the other on New Jersey.”
Wall Street Journal, November 23
Traveling from Point A to Point B can be challenging for New Jerseyans with disabilities and older adults seeking to access destinations both within and beyond their county of residence. Since 2021, researchers at the Rutgers Voorhees Transportation Center (VTC), part...
Read Report In Pennsylvania, when Governor Josh Shapiro’s administration set out to train 175 state employees on how to use ChatGPT responsibly, the state reported saving an average of 95 minutes when they utilized it for drafting and summarizing lengthy documents. As...
The Heldrich Center for Workforce Development, working with the Rutgers Child Care Research Collaborative, has released a new brief highlighting the challenges New Jersey’s child care workforce faces when caring for children who may have special needs and identifying...
In early October Bloustein alumnus Dan Dominguez, PP, AICP, MCRP ’14, the City of New Brunswick Director of Policy and Development, delivered the school's annual Stuart Meck Memorial Lecture in Land Use Law and Affordable Housing. Dan discussed the evolution of urban...
Bloustein School students secure top honors in national competition featuring 40 graduate program teams from across the United States. A team of Master of Health Administration (MHA) students from Rutgers University–New Brunswick's Edward...